Descartes-15 is under clinical development by Cartesian Therapeutics and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData, Phase I drugs for Refractory Multiple Myeloma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Descartes-15’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Descartes-15 overview
Descartes-15 is under development for the treatment of relapsed and refractory multiple myeloma and autoantibody-associated autoimmune diseases (AAAD). The therapeutic candidate is an chimeric antigen receptor cell therapy based on cartesian's proprietary technology. It acts by targeting B Cell maturation antigen (BCMA). It is administered through parenteral route.
It was under development for the treatment of solid tumors.
Cartesian Therapeutics overview
Cartesian Therapeutics (Cartesian), formerly Selecta Biosciences, is a biopharmaceutical company that develops immunotherapies and vaccines for the treatment and prevention of human diseases. The company’s pipeline products include SEL-212, SEL-403, SEL-302 and SEL-018. It utilizes a synthetic vaccine particle (SVP) technology platform to incorporate a wide range of antigens and immunomodulators for the development of products that induce antigen-specific tolerance or activate the immune system. Cartesian develops products for the treatment of infections, central nervous system diseases, cancer, allergies, cardiovascular diseases, autoimmunity, metabolic diseases, asthma and acute and chronic inflammatory conditions. The company collaborates with pharma companies to develop drugs for allergy and autoimmune diseases. Cartesian is headquartered in Watertown, Massachusetts, the US
For a complete picture of Descartes-15’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
